Ribociclib: tested with established drugs

36 studies: they are given beside it. Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast CancerRecruitingNCT07214532Not applicable Report a problem
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingNCT05467891Phase 2 Report a problem
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast CancerCompletedNCT03822468Phase 2Results posted Report a problem
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.CompletedNCT03671330Phase 2Results posted Report a problem
Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT03096847Phase 3Results posted Report a problem
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast CancerCompletedNCT03078751Phase 2Results posted Report a problem
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine TumorsCompletedNCT03070301Phase 2Results posted Report a problem
LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to ChemotherapyCompletedNCT02985125Phase 1/2Results posted Report a problem
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCCompletedNCT02941926Phase 3Results posted Report a problem
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.CompletedNCT02732119Phase 1/2Results posted Report a problem
Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast CancerActive, not recruitingNCT02712723Phase 2Results posted Report a problem
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial CancerCompletedNCT02657928Phase 2Results posted Report a problem
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.CompletedNCT02657343Phase 1/2Results posted Report a problem
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast CancerCompletedNCT02632045Phase 2Results posted Report a problem
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast CancerCompletedNCT02586675Phase 1Results posted Report a problem
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma ExpressionTerminatedNCT02555189Phase 1/2Results posted Report a problem
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.CompletedNCT02422615Phase 3Results posted Report a problem
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast CancerCompletedNCT02278120Phase 3Results posted Report a problem
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast CancerCompletedNCT01958021Phase 3Results posted Report a problem
A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)TerminatedNCT01919229Phase 2Results posted Report a problem
Phase IIIb Study of Ribociclib + ET in Early Breast CancerActive, not recruitingNCT05827081Phase 3 Report a problem
Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast CancerActive, not recruitingNCT05296746Phase 2 Report a problem
Roll-over Study to Allow Continued Access to RibociclibActive, not recruitingNCT05161195Phase 4 Report a problem
FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast CancerActive, not recruitingNCT03944434Phase 2 Report a problem
Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast CancerCompletedNCT03555877Phase 2 Report a problem
Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast CancerWithdrawnNCT03081234Phase 3 Report a problem
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian CancerCompletedNCT03056833Phase 1 Report a problem
Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by SurgeryCompletedNCT03009201Phase 1 Report a problem
Next Generation Personalized Neuroblastoma TherapyTerminatedNCT02780128Phase 1 Report a problem
Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 NegativeCompletedNCT02754011Phase 1 Report a problem
Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid TumorsTerminatedNCT02703571Phase 1 Report a problem
A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast CancerCompletedNCT02599363Phase 1 Report a problem
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or LymphomaTerminatedNCT02414724Phase 1 Report a problem
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.CompletedNCT02292550Phase 1 Report a problem
Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.CompletedNCT02154776Phase 1 Report a problem
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast CancerCompletedNCT01857193Phase 1 Report a problem

← Ribociclib